Aurinia Pharmaceuticals Inc. reports news centered on its autoimmune-disease biopharmaceutical business, led by LUPKYNIS (voclosporin), an FDA-approved oral therapy for adult patients with active lupus nephritis. Recurring updates cover product sales, total revenue, license, collaboration and royalty revenue, and business progress tied to commercialization of LUPKYNIS.
Company news also includes pipeline development for aritinercept, a dual BAFF and APRIL inhibitor being developed for autoimmune diseases, as well as collaboration activity with Otsuka, financial guidance, share repurchase activity, executive appointments, board matters and shareholder governance commentary.
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the completion of the last patient visit in the Phase 2/3 AUDREY™ clinical study for voclosporin ophthalmic solution (VOS), targeting dry eye syndrome (DES). The study enrolled 509 subjects and compared VOS with a vehicle over 12 weeks. Promising efficacy results were previously noted against Restasis®. Top-line results are expected in Q4 2020, highlighting VOS's potential as a leading calcineurin inhibitor in ophthalmic treatments.